Booth No. : A32

Presentation Representative : Masaru Tomita

Person in Charge of the Project : Masaru Tomita

Bio-venture company from SFC being listed at the Tokyo Stock Exchange Mothers Market


We have developed a novel technology for high-throughput metabolome analysis, which can simultaneously quantify a large amount of metabolites.
Based on this technology, we founded Human Metabolome Technologies, Inc. (HMT), and the company was listed on the Tokyo Stock Exchange Mothers in December, 2013.
Using this technology, HMT has discovered a biomarker of major depression, Ethanolamine Phosphate (EAP), and is trying to make the diagnostic service commercial world-wide.